Using a cohort of 99 NSCLC patients treated with ICI, Nabet et al. found that high baseline normalized bTMB, low baseline peripheral CD8 T cell level and early changes in ctDNA dynamics after a single ICI infusion were associated with durable clinical benefit. Here, CD8A is linked to non-small cell lung carcinoma.